Serum IL-17 and IL-23 Levels and Autoantigen-specific Th17 Cells Are Elevated in Patients with ANCA-associated Vasculitis
Overview
Nephrology
Authors
Affiliations
Background: The Th17 subset has been implicated in the pathogenesis of a number of autoimmune diseases. However, little is known about its role in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). We measured serum levels of IL-17A and associated upstream cytokines and the frequency of IL-17-producing autoantigen-specific T cells in patients with AAV.
Methods: ELISA on sera from acute (n = 28) and convalescent (n = 65) patients with AAV from Hammersmith Hospital was performed for IL-17A and the associated upstream cytokines IL-23, IL-6 and IL-1beta, as well as the Th1 cytokine IFN-gamma. ELISPOT was performed to measure autoantigen-specific recall T cell responses in convalescent patients and the frequency of IL-17- and IFN-gamma-producing cells.
Results: Serum IL-17A and IL-23 levels were significantly elevated in acute AAV patients compared to healthy controls (P < 0.01 and P < 0.001, respectively), but importantly, remained elevated in a proportion of convalescent patients. By contrast, no significant differences in IFN-gamma levels were detected between patient groups and controls. Patients with elevated levels of IL-23 compared to those with low IL-23 had more active disease as measured by Birmingham Vasculitis Activity Score (P < 0.05) and had higher ANCA titres (P < 0.05). Critically, immunosuppressive therapy did not always effectively suppress IL-23 or IL-17 production. Additionally, autoantigen-specific IL-17-producing, but not IFN-gamma-producing, cells were significantly elevated in patients during disease convalescence compared to healthy controls.
Conclusions: These data implicate the Th17 axis and specifically IL-23 as mediators of more severe disease in AAV. Their persistence despite conventional treatment may contribute to high relapse rates.
Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis.
Hua L, Xie M Ther Adv Respir Dis. 2025; 19:17534666251318615.
PMID: 39980304 PMC: 11843704. DOI: 10.1177/17534666251318615.
The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium.
McGovern D, Jones R, Jayne D, Smith R Drugs. 2025; 85(3):325-341.
PMID: 39969779 DOI: 10.1007/s40265-024-02143-z.
Hussein W, Ramadan H, Labib S, Hegazy G, Shaker O, Yusuf S Biologics. 2024; 18:327-337.
PMID: 39555123 PMC: 11568774. DOI: 10.2147/BTT.S493191.
Immune checkpoint molecules performance in ANCA vasculitis.
Anton-Pampols P, Martinez Valenzuela L, Fernandez Lorente L, Quero Ramos M, Gomez Preciado F, Goma M RMD Open. 2024; 10(4).
PMID: 39537557 PMC: 11575324. DOI: 10.1136/rmdopen-2024-004660.
Engesser J, Khatri R, Schaub D, Zhao Y, Paust H, Sultana Z Nat Commun. 2024; 15(1):8220.
PMID: 39300109 PMC: 11413367. DOI: 10.1038/s41467-024-52525-w.